Serum Levels of Soluble TNFα Receptors (sTNFR1 and sTNFR2) during Corticosteroid Treatment in Patients with Graves' Ophthalmopathy

Immunological Investigations

Volumn 33, Issue 1, 2004, Pages 61-68

  Myśliwiec, Janusz ^a   Krȩtowski, Adam ^a   Stȩpien, Agnieszka ^a   Kinalska, Ida ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Corticosteroids; Graves' ophthalmopathy; sTNFR1; sTNFR2

Indexed keywords

CORTICOSTEROID; METHYLPREDNISOLONE; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG EFFICACY; ENDOCRINE OPHTHALMOPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; SERUM;

EID: 19244375333     PISSN: 08820139     EISSN: None     Source Type: Journal    
DOI: 10.1081/IMM-120027685     Document Type: Article

References (21)

1. Barnes, P. J. (1998). Antiinflammatory actions of corticosteroids: molecular mechanisms. Clin. Sci. 84:557-572.
2. Bazzoni, F., Beutler, B. (1996). The tumor necrosis factor ligand and receptor families. N. Engl. J. Med. 334:1717-1725.
3. Debets, R., Savelkoul, H. F. J. (1996). Cytokines as cellular communicators. Mediat. Inflamm. 5:417-423.
4. Heufelder, A. E., Bahn, R. S. (1993). Detection and localization of cytokine immunoreactivity in retroocular connective tissue in Graves' ophthalmopathy. Eur. J. Clin. Investig. 23:10-17.
5. Hiromatsu, Y., Yang, D., Bednarczuk, T., Miyake, I., Nonaka, K., Inoue, Y. (2000). Cytokine profiles in eye muscle tissue and orbital fat from patients with thyroid associated ophthalmopathy. J. Clin. Endocrinol. Metab. 85:1194-1201.
6. Kazim, M., Trokel, S., Moore, S. (1991). Treatment of acute Graves' orbitopathy. Ophthalmology 98:1443-1448.
7. Keil, M., Pec, M. K., Schenn, G., Grunberger, T., Kramer, G., Fugger, R., Steininger, R., Muhlbacher, F., Balcke, P., Stockenhuber, F. (1994). Value of serum soluble tumour necrosis factor concentrations in the diagnosis and prognosis of renal graft rejection. Nephrol. Dial. Transplant. 9:915-919.
8. Leonardi, A., Borghesan, F., DePaoli, M., Plebani, M., Secchi, A. G. (1998). Procollagens and inflammatory cytokine concentrations in tarsal and limbal vernal keratoconjunctivitis. Exp. Eye Res. 67:105-112.
9. Levine, S., Logun, C., Chopra, D. P., Rhim, J. S., Shelhamer, J. H. (1996). Protein kinase C, Interleukin-1β, and corticosteroids regulate shedding of the type I, 55 kDa TNF receptor from human airway epithelial cells. Am. J. Respir. Cell Mol. Biol. 14:254-261.
10. Liu, J., Marino, M. W., Wing, G., Grail, D., Dunn, A., Bettadapura, J., Slavin, A., Old, L., Bernard, C. C. (1998). TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelinisation. Nat. Med. 4:78-83.
11. Mourits, M., Koorneef, L., Wiersinga, W. M., Prummel, M. F., Berghout, A., Gaag, R. D. (1989). Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach. Br. J. Ophtalmol. 73:639-644.
12. Mysliwiec, J., Kretowski, A., Topolska, J., Siewko, K., Jakubczyk, D., Szelachowska, M., Mikita, A., Kinalska, I. (2001). Serum Th1 and Th2 profile cytokine level changes in patients with Graves' ophthalmopathy treated with corticosteroids. Horm. Metab. Res. 33:739-743.
13. Natt, N., Bahn, R. S. (1997). Cytokines in the evolution of Graves' ophthalmopathy. Autoimmunity 26:129-133.
14. Pleyer, U., Milani, J. K., Ruckert, D., Rieck, P., Mondino, B. J. (1997). Determinations of serum tumor necrosis factor alpha in corneal allografts. Ocul. Immunol. Inflamm. 5:149-155.
15. Ramanathan, M. A. (1997). Physiochemical modelling approach for estimating the stability of soluble receptor-bound tumor necrosis factor-alpha. Cytokine 9:19-26.
16. Robak, T., Gladalska, A., Stepien, H. (1998). The tumor necrosis factor family of receptors/ligands in the serum of patients with rheumatoid arthritis. Eur. Cytokine Netw. 9:145-154.
17. Shimizu, T., Tomita, Y., Son, K., Nishinarita, S., Sawada, S., Horie, T. (2000). Elevation of serum soluble tumour necrosis factor receptors in patients with polymyositis and dermatomyositis. Clin. Rheumatol. 19:352-359.
18. Sytwu, H. K., Liblau, R. S., McDevitt, H. O. (1996). The roles of Fas/Apo-1(CD95) and TNF in antigen-induced programmed cell death in T cell receptor transgenic mice. Immunity 5:17-30.
19. Valyasevi, R. W., Jyonouchi, S. C., Dutton, C. M., Munsakul, N., Bahn, R. (2001). Effect of tumor necrosis factor-alpha, interferon-gamma, and transforming growth factor-beta on adipogenesis and expression of thyrotropin receptor in human orbital preadipocyte fibroblasts. J. Clin. Endocrinol. Metab. 86:903-908.
20. Zhou, T., Edwards, C. K., Yang, P., Wang, Z., Bluethmann, H., Mountz, J. D. (1996). Greatly accelerated lymphadenopathy and autoimmune disease in lpr mice lacking tumor necrosis factor receptor 1. J. Immunol. 156:2661-2665.
21. Ziegenhagen, M. W., Fitschen, J., Martinet, N., Schlaak, M., Muller-Quernheim, J. (2000). Serum level of soluble tumour factor receptor II (75 kDa) indicates inflammatory activity of sarcoidosis. J. Intern. Med. 248:33-41.